• The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights.
• The deal enables Servier to potentially bring additional indications and accessibility of TIBSOVO^® to patients in Greater China (including mainland, Hong Kong, Macau, and Taiwan) and Singapore.
• CStone to receive up to 50 million USD to monetize some future cash flow while recouping its historical investment on the asset.

Under the terms of the Agreement, CStone will transfer the TIBSOVO business, in the territories, to Servier for 44 million USD, followed by a payment of up to 6 million USD upon completion of the transition. As a result, the licensing agreement with Servier will be terminated and CStone will be released from payment obligations of any remaining development and commercialization milestones. In 2021, Servier acquired the oncology business of Agios Pharmaceuticals that had, since 2018, an exclusive collaboration and license agreement with CStone to develop and commercialize TIBSOVO in Greater China and Singapore.

"We have been working closely with Servier over the past two years, and actively advancing the development and commercialization of TIBSOVO in Asian regions, positioning it as the first IDH1 inhibitor in greater China territories. We are very proud of what CStone has accomplished and the significant efforts in the commercialization of this innovative medicine." said Dr. Jason Yang, CEO of CStone, "As the holder of its global rights, Servier is the ideal partner to further develop and commercialize TIBSOVO to maximize its value for patients in the Asian territories. This transaction will also enable us to focus on developing more first-in-class and best-in-class therapies for patients globally."

"TIBSOVO marks a transformative breakthrough in cancer therapy for patients with an IDH1 mutation. Aligned with our global oncology strategy, this agreement empowers Servier to potentially deliver pioneering therapeutic options to patients with rare and challenging cancers in Greater China and Singapore" said, Philippe Gonnard, Executive Vice President, Global Product Strategy at Servier. "This milestone underscores Servier's commitment to fortifying our oncology presence in Asia and our dedicated to oncology patients worldwide."

In January 2022, the National Medical Products Administration (NMPA) of China approved TIBSOVO for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) who have a susceptible IDH1 mutation. Since its launch in mainland China, TIBSOVO is now accessible in close to 80 hospitals and DTP pharmacies and is covered by commercial insurance programs in about 100 cities. TIBSOVO has been included in over 6 clinical guidelines and consensus based on its strong clinical profile. Additionally, the Named Patient Program (NPP) for TIBSOVO has been launched in Hong Kong, Taiwan, and Singapore.